Entering text into the input field will update the search result below

AbbVie: With Banks In Distress, Look At Recession-Resilient Healthcare Companies

Mar. 14, 2023 3:17 AM ETAbbVie Inc. (ABBV)7 Comments
Daniel Schönberger profile picture
Daniel Schönberger


  • With the collapse of SVB Financial Group dominating the news and sending shockwaves again, we should look at recession-resilient companies like AbbVie.
  • In fiscal 2022, AbbVie reported solid results, but growth slowed down.
  • Although the next two years will get difficult due to Humira patent expiration and declining sales, growth will return after 2025.
  • And AbbVie is interesting for its dividend yield and is at least fairly valued right now.

Dollar banknote & market data


In my last article about AbbVie (NYSE:ABBV) published in June 2022 I saw the company being not the perfect investment, but largely recession-proof and fairly valued at that point. Now as the signs for economic distress are growing, it

Data by YCharts

AbbVie: Income Statement for fiscal 2022

AbbVie Annual Report 2022

Humira sales could be replaced by Skyrizi and Rinvoq sales

AbbVie JPM Healthcare Conference Presentation

AbbVie: Several anticipated key pipeline events in 2023 and 2024

AbbVie Pipeline Presentation

Data by YCharts

This article was written by

Daniel Schönberger profile picture
Part-time investor and contributor for Seeking Alpha since 2016. My analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (from large cap to small cap companies). My academic background is in sociology and I hold a Master’s Degree in Sociology (with main emphasis on organizational and economic sociology) and a Bachelor’s Degree in Sociology and History.I also write about investing, economy and similar topics on Medium: https://medium.com/@danielschonberger

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.